In the preliminary test, substantial differences were not observed between the with and without pre- or post-operative chemotherapy for CDX2-low CRC in terms of DFS and OS in days (DFS: 243 versus 247 days; P = 0.73, OS: 1016 versus 1363 days; P = 0.69, Fig. 3a, b). This evidence concerns the gene CDX2 and colorectal carcinoma.